Multiple sclerosis: Pro- and anti-inflammatory cytokines and metalloproteinases are affected differentially by treatment with IFN-β

Journal of Neuroimmunology

Volumn 108, Issue 1-2, 2000, Pages 236-243

  Özenci, Volkan ^a   Kouwenhoven, Mathilde ^a   Teleshova, Natalia ^a   Pashenkov, Mikhail ^a   Fredrikson, Sten ^a   Link, Hans ^a  

^a KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

Author keywords

Cytokines; ELISPOT; Interferon beta; Metalloproteinases; Multiple sclerosis

Indexed keywords

BETA INTERFERON; BETA1A INTERFERON; CYTOKINE; GAMMA INTERFERON; INTERFERON BETA SERINE; INTERLEUKIN 10; INTERLEUKIN 6; MESSENGER RNA; METALLOPROTEINASE; STROMELYSIN; TUMOR NECROSIS FACTOR ALPHA;

ADULT; ARTICLE; CLINICAL ARTICLE; FEMALE; HUMAN; HUMAN CELL; IN SITU HYBRIDIZATION; INFLAMMATION; MALE; MULTIPLE SCLEROSIS; PRIORITY JOURNAL;

CELLS, CULTURED; CYTOKINES; FEMALE; GENE EXPRESSION REGULATION; GENE EXPRESSION REGULATION, ENZYMOLOGIC; HUMANS; IN SITU HYBRIDIZATION; INFLAMMATION; INTERFERON TYPE II; INTERFERON-BETA; INTERLEUKINS; LEUKOCYTES, MONONUCLEAR; LONGITUDINAL STUDIES; MALE; MATRIX METALLOPROTEINASE 3; MATRIX METALLOPROTEINASE 7; MATRIX METALLOPROTEINASE 9; MATRIX METALLOPROTEINASES; MIDDLE AGED; MULTIPLE SCLEROSIS; RNA, MESSENGER; TISSUE INHIBITOR OF METALLOPROTEINASE-1; TUMOR NECROSIS FACTOR-ALPHA;

EID: 0034256059     PISSN: 01655728     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0165-5728(00)00281-2     Document Type: Article

References (26)

1. Barnes, A., 1998. Measurements of serum cytokines. Lancet 352, 324-325.
2. Brod, S.A., Nelson, L.D., Khan, M., Wolinsky, J.S., 1997. IFN-beta 1b treatment of relapsing multiple sclerosis has no effect on CD3-induced inflammatory or counterregulatory anti-inflammatory cytokine secretion ex vivo after nine months. Int. J. Neurosci. 90, 135-144.
3. Chandler, S., Miller, K.M., Lury, J., Corkill, D., Anthony, D.C., Adams, S.E., Gearing, A.J., 1997. Matrix metalloproteinases, tumor necrosis factor and multiple sclerosis: an overview. J. Neuroimmunol. 72, 155-161.
4. Czerkinsky, C.C., Andersson, G., Ekre, H.-P., Nilsson, L.A., Klareskog, L., Ouchterlony, Ö., 1988. Reverse ELISPOT assay for clinical analysis of cytokine production. I. Enumeration of gamma-interferon secreting cells. J. Immunol. Methods 110, 29-36.
5. DeClerck, Y.A., Yean, T.-D., Ratzkin, B.J., Lu, H.S., Langley, K.E., 1989. Purification and characterization of two related but distinct metalloprotease inhibitors secreted by bovine aortic endothelial cells. J. Biol. Chem. 264, 17 445-17 450.
6. Dhib-Jalbut, S., Jiang, H., Williams, G.J., 1996. The effect of interferon beta-1b on lymphocyte-endothelial cell adhesion. J. Neuroimmunol. 71, 215-222.
7. Docherty, A.J., O'Connel, J., Crabbe, T., Angal, S., Murphy, G., 1992. The matrix metalloproteinases and their neutral inhibitors: prospects for treating degenerative tissue diseases. TIBTECH 10, 200-207.
8. Duddy, M.E., Armsrong, M.A., Crockard, A.D., Hawkins, S.A., 1999. Changes in plasma cytokines induced by interferon-β1a treatment in patients with multiple sclerosis. J. Neuroimmunol. 101, 98-109.
9. European Study Group on Interferon β-1b in Secondary Progressive MS, 1998. Placebo-controlled multicenter randomized trial of interferon β-1b in treatment of secondary progressive multiple sclerosis. Lancet 352, 1491-1497.
10. Jacobs, L.D., Cookfair, D.L., Rudick, R.A., Herndon, R.M., Richert, J.R., Salazar, A.M., Fischer, J.S., Goodkin, D.E., Granger, C.V., Simon, J.H., Alam, J.J., Bartoszak, D.M., Bourdette, D.N., Braiman, J., Brownscheidle, C.M., Coats, M.E., Cohan, S.L., Dougherty, D.S., Kinkel, R.P., Mass, M.K., Munschauer, F.E., Pnore, R.L., Pullicino, P.M., Scherokman, B.J., Whitham, R.H. et al., 1996. Intramuscular interferon beta-la for disease progression in relapsing multiple sclerosis. Ann. Neurol. 39, 285-294.
11. Kurtzke, J.F., 1983. Rating neurological impairment in multiple sclerosis: an expanded disability status scale (EDSS). Neurology 33, 1444-1452.
12. Lee, M.A., Palace, J., Stabler, G., Ford, J., Gearing, A., Miller, K., 1999. Serum gelatinase B, TIMP-1 and TIMP-2 levels in multiple sclerosis: a longitudinal clinical and MRI study. Brain 122, 191-197.
13. Leppert, D., Waubant, E., Burk, M.R., Oksenberg, J.R., Hauser, S.L., 1996. Interferon beta-lb inhibits gelatinase secretion and in vitro migration of human T cells: a possible mechanism for treatment efficacy in multiple sclerosis. Ann. Neurol. 40, 846-852.
14. Link, J., Söderström, M., Ljungdahl, A., Höjeberg, B., Olsson, T., Xu, Z., Fredrikson, S., Wang, Z.-Y., Link, H., 1994. Organ-specific autoantigens induce interferon-γ and interleukin-4 mRNA expression in mononuclear cells in multiple sclerosis and myasthenia gravis. Neurology 44, 728-734.
15. Louis, J.C., Magal, E., Takayama, S., Varon, S., 1993. CNTF protection of oligodendrocytes against natural and tumor necrosis factor-α-induced death. Science 259, 689-692.
16. Poser, C.M., Paty, D.W., Scheinberg, L., McDonald, W.I., Davis, F.A., Ebers, G.C., Johnson, K.P., Sibley, WA., Silberberg, D.H., Tourtellotte, W.W., 1983. New diagnostic criteria for multiple sclerosis: guidelines for research protocols. Ann. Neurol. 13, 227-231.
17. Rep, M.H., Schrijver, H.M., van Lopik, T., Hintzen, R.Q., Roos, M.T., Ader, H.J., Polman, C.H., van Lier, R.A., 1999. Interferon (IFN)-beta treatment enhances CD95 and interleukin-10 expression but reduces interferon-gamma producing T cells in MS patients. J. Neuroimmunol. 96, 92-100.
18. Rudick, R.A., Ransohoff, R.M., Lee, J.C., Peppler, R., Yu, M., Mathisen, P.M., Tuohy, V.K., 1998. In vivo effects of interferon beta-1a on immunosuppressive cytokines in multiple sclerosis. Neurology 50, 1294-1300.
19. Stuve, O., Dooley, N.P., Uhm, J.H., Antel, J.P., Francis, G.S., Williams, G., Yong, V.W., 1996. Interferon β-1b decreases the migration of T lymphocytes in vitro: effects on matrix metalloproteinase-9. Ann. Neurol. 40, 853-863.
20. The IFNB Multiple Sclerosis Study Group, 1995. Interferon beta-lb in the treatment of multiple sclerosis: final outcome of the randomized controlled trial. Neurology 45, 1277-1285.
21. Trojano, M., Avolio, C., Liuzzi, G.M., Ruggieri, M., Defazio, G., Liguori, M., Santacroce, M.P., Paolicelli, D., Giuliani, F., Riccio, P., Livrea, P., 1999. Changes of serum sICAM-1 and MMP-9 induced by rIFNbeta-1b treatment in relapsing-remitting MS. Neurology 22, 1402-1408.
22. Uhm, J.H., Dooley, N.P., Stuve, O., Francis, G.S., Duquette, P., Antel, J.P., Yong, V.W., 1999. Migratory behaviour of lymphocytes isolated from multiple sclerosis patients: effects of interferon beta-lb therapy. Ann. Neurol. 46, 319-324.
23. Waubant, E., Goodkin, D.E., Gee, L., Bacchetti, P., Sloan, R., Stewart, T., Anderson, P.-B., Stabler, G., Miller, K., 1999. Serum MMP-9 and TIMP-1 levels are related to MRI activity in relapsing multiple sclerosis. Neurology 53, 1397-1401.
24. Özenci, V., Kouwenhoven, M., Huang, Y.-M., Xiao, B.-G., Kivisäkk, P., Fredrikson, S., Link, H., 1999a. Multiple sclerosis: levels of IL-10 secreting blood mononuclear cells are low in untreated patients but augmented during IFN-β-1b treatment. Scand. J. Immunol. 49, 554-561.
25. Özenci, V., Rinaldi, L., Teleshova, N., Matusevicius, D., Kivisäkk, P., Kouwenhoven, M., Link, H., 1999b. Metalloproteinases and their tissue inhibitors in multiple sclerosis. J. Autoimmun. 12, 297-303.
26. Özenci, V., Kouwenhoven, M., Huang, Y.-M., Kivisäkk, P., Link, H., 2000. Multiple sclerosis is associated with an imbalance between TNF-α and IL-10 secreting blood cells that is corrected by IFN-beta treatment. Clin. Exp. Immunol. 120, 147-153.